Response To: the Role of Dual Inhibition of EGFR and Vascular EGF(R) in the Treatment of NSCLC with EGFR Mutation
Hongyun Zhao,Zhonghan Zhang,Li Zhang
DOI: https://doi.org/10.1016/j.jtho.2021.07.013
2021-01-01
Abstract:We thank Dr. Kim et al. for their interest in our article and the thoughtful comments. We totally agreed that not all the patients benefit from EGFR tyrosine kinase inhibitors (TKIs) plus antivascular endothelial growth factor or vascular endothelial growth factor receptor regimen. For example, in the ACTIVE (CTONG1706) study, we observed that patients concomitant with TP53 mutation had a prolonged progression-free survival (PFS) tendency. Because it was only a subgroup analysis, well-designed prospective clinical studies are needed to answer this question. Inspired by the ACTIVE study, our team set up another study to evaluate the efficacy and safety of osimertinib monotherapy and the combination of osimertinib and chemotherapy in patients with advanced NSCLC with concurrent EGFR and TP53 mutation. The results of this ongoing phase 3 study (NCT04695925) are eagerly awaited.1ClinicalTrials.govPhase III study comparing osimertinib monotherapy to combination therapy with osimertinib,carboplatin and pemetrexed for untreated patients with advanced non-squamous non-small cell lung cancer with concurrent EGFR and TP53 mutations (TOP).https://clinicaltrials.gov/ct2/show/NCT04695925Date accessed: July 17, 2021Google Scholar For first-line EGFR TKI monotherapy, in multiple randomized controlled trials, comparing EGFR TKIs against chemotherapy or other EGFR TKIs in patients with NSCLC with activating EGFR mutations, efficacy and survival seemed to differ according to exon 19 deletion (ex19del) and exon 21 L858R (ex21L858R) mutation subtype (Tables 1 and 2).2Rosell R. Carcereny E. Gervais R. et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.Lancet Oncol. 2012; 13: 239-246Abstract Full Text Full Text PDF PubMed Scopus (4284) Google Scholar, 3Wu Y.L. Zhou C. Liam C.K. et al.First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.Ann Oncol. 2015; 26: 1883-1889Abstract Full Text Full Text PDF PubMed Scopus (515) Google Scholar, 4Zhou C. Wu Y.L. Chen G. et al.Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).Ann Oncol. 2015; 26: 1877-1883Abstract Full Text Full Text PDF PubMed Scopus (337) Google Scholar, 5Mitsudomi T. Morita S. Yatabe Y. et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.Lancet Oncol. 2010; 11: 121-128Abstract Full Text Full Text PDF PubMed Scopus (3474) Google Scholar, 6Shi Y.K. Wang L. Han B.H. et al.First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.Ann Oncol. 2017; 28: 2443-2450Abstract Full Text Full Text PDF PubMed Scopus (171) Google Scholar, 7Ramalingam S.S. O’Byrne K. Boyer M. et al.Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.Ann Oncol. 2016; 27: 1363Abstract Full Text Full Text PDF PubMed Scopus (1) Google Scholar, 8Wu Y.L. Cheng Y. Zhou X. et al.Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.Lancet Oncol. 2017; 18: 1454-1466Abstract Full Text Full Text PDF PubMed Scopus (634) Google Scholar, 9Mok T.S. Cheng Y. Zhou X. et al.Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations.Drugs. 2021; 81: 257-266Crossref PubMed Scopus (21) Google Scholar, 10Yang J.C. Wu Y.L. Schuler M. et al.Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.Lancet Oncol. 2015; 16: 141-151Abstract Full Text Full Text PDF PubMed Scopus (1157) Google Scholar, 11Schuler M. Tan E.H. O’Byrne K. et al.First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.J Cancer Res Clin Oncol. 2019; 145: 1569-1579Crossref PubMed Scopus (26) Google Scholar, 12Soria J.C. Ohe Y. Vansteenkiste J. et al.Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer.N Engl J Med. 2018; 378: 113-125Crossref PubMed Scopus (2332) Google Scholar, 13Planchard D. Boyer M.J. Lee J.S. et al.Postprogression outcomes for osimertinib versus standard-of-care EGFR-TKI in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer.Clin Cancer Res. 2019; 25: 2058-2063Crossref PubMed Scopus (39) Google Scholar, 14Cheng Y. He Y. Li W. et al.Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study.Target Oncol. 2021; 16: 165-176Crossref PubMed Scopus (22) Google Scholar Moreover, two studies of individual patient data meta-analysis revealed that EGFR TKIs had 42.9% to 50% greater PFS benefit with ex19del than ex21L858R in comparison with chemotherapy.15Lee C.K. Wu Y.L. Ding P.N. et al.Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis.J Clin Oncol. 2015; 33: 1958-1965Crossref PubMed Scopus (243) Google Scholar,16Lee C.K. Davies L. Wu Y.L. et al.Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival.J Natl Cancer Inst. 2017; 109: djw279Crossref Scopus (156) Google Scholar In the combination therapy setting, subgroup analysis of the JO25567,17Seto T. Kato T. Nishio M. et al.Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.Lancet Oncol. 2014; 15: 1236-1244Abstract Full Text Full Text PDF PubMed Scopus (581) Google Scholar,18Yamamoto N. Seto T. Nishio M. et al.Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: survival follow-up results of the randomized JO25567 study.Lung Cancer. 2021; 151: 20-24Abstract Full Text Full Text PDF PubMed Scopus (22) Google Scholar NEJ026,19Saito H. Fukuhara T. Furuya N. et al.Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.Lancet Oncol. 2019; 20: 625-635Abstract Full Text Full Text PDF PubMed Scopus (308) Google Scholar,20Maemondo M. Fukuhara T. Saito H. et al.NEJ026: final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.J Clin Oncol. 2020; 38 (9506–9506)Google Scholar and ACTIVE21Zhao H. Yao W. Min X. et al.Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC: the phase III ACTIVE study (CTONG1706).J Thorac Oncol. 2021; 16: 1533-1546Abstract Full Text Full Text PDF PubMed Scopus (21) Google Scholar studies revealed that there was a considerable PFS difference in patients with NSCLC with ex19del, whereas those with ex21L858R derived no significant PFS benefit from EGFR TKIs plus antiangiogenic agents. Nevertheless, there was no difference in overall survival between ex19del and ex21L858R in EGFR TKI monotherapy trials.16Lee C.K. Davies L. Wu Y.L. et al.Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival.J Natl Cancer Inst. 2017; 109: djw279Crossref Scopus (156) Google Scholar Furthermore, some combination therapy studies, such as the ARTEMIS22Zhou Q. Wu Y.L. Cheng Y.C. et al.CTONG 1509: phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC.Ann Oncol. 2019; 30: v603Abstract Full Text PDF Google Scholar and REALY,23Nakagawa K. Garon E.B. Seto T. et al.Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol. 2019; 20: 1655-1669Abstract Full Text Full Text PDF PubMed Scopus (258) Google Scholar reported that PFS benefit was consistent in both ex19del and ex21L858R subgroups.Table 1PFS of Patients With NSCLC Harboring EGFR Exon 19 Deletion and 21L858R MutationTrialsTreatmentExon 19 DeletionExon 21 L858R MutationPFS (mo)HR (95% CI)PFS (mo)HR (95% CI)EURTAC2Rosell R. Carcereny E. Gervais R. et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.Lancet Oncol. 2012; 13: 239-246Abstract Full Text Full Text PDF PubMed Scopus (4284) Google ScholarErlotinib11.00.300 (0.180–0.500)8.40.550 (0.290–1.020)Chemotherapy4.66.0ENSURE3Wu Y.L. Zhou C. Liam C.K. et al.First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.Ann Oncol. 2015; 26: 1883-1889Abstract Full Text Full Text PDF PubMed Scopus (515) Google ScholarErlotinib11.10.200 (0.110–0.370)7.10.570 (0.310–1.050)Chemotherapy4.28.3OPTIMAL4Zhou C. Wu Y.L. Chen G. et al.Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).Ann Oncol. 2015; 26: 1877-1883Abstract Full Text Full Text PDF PubMed Scopus (337) Google ScholarErlotinibNR0.130 (0.070–0.250)NR0.260 (0.140–0.490)ChemotherapyNRNRWJTOG34055Mitsudomi T. Morita S. Yatabe Y. et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.Lancet Oncol. 2010; 11: 121-128Abstract Full Text Full Text PDF PubMed Scopus (3474) Google ScholarGefitinibNR0.453 (0.268–0.768)NR0.514 (0.294–0.899)ChemotherapyNRNRCONVINCE6Shi Y.K. Wang L. Han B.H. et al.First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.Ann Oncol. 2017; 28: 2443-2450Abstract Full Text Full Text PDF PubMed Scopus (171) Google ScholarIcotinib11.20.660 (0.380–1.140)11.10.760 (0.430–1.330)Chemotherapy8.07.8ARCHER 1009 and A74710287Ramalingam S.S. O’Byrne K. Boyer M. et al.Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.Ann Oncol. 2016; 27: 1363Abstract Full Text Full Text PDF PubMed Scopus (1) Google ScholarDacomitinib14.60.585 (0.335–1.024)10.00.955 (0.421–2.168)Erlotinib10.09.0ARCHER 10508Wu Y.L. Cheng Y. Zhou X. et al.Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.Lancet Oncol. 2017; 18: 1454-1466Abstract Full Text Full Text PDF PubMed Scopus (634) Google Scholar,9Mok T.S. Cheng Y. Zhou X. et al.Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations.Drugs. 2021; 81: 257-266Crossref PubMed Scopus (21) Google ScholarDacomitinib16.50.550 (0.410–0.750)12.60.630 (0.440–0.880)Gefitinib9.29.8LUX-Lung 310Yang J.C. Wu Y.L. Schuler M. et al.Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.Lancet Oncol. 2015; 16: 141-151Abstract Full Text Full Text PDF PubMed Scopus (1157) Google ScholarAfatinibNR0.280 (0.180–0.440)NR0.730 (0.460–1.170)ChemotherapyNRNRLUX-Lung 610Yang J.C. Wu Y.L. Schuler M. et al.Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.Lancet Oncol. 2015; 16: 141-151Abstract Full Text Full Text PDF PubMed Scopus (1157) Google ScholarAfatinibNR0.200 (0.130–0.330)NR0.320 (0.190–0.520)ChemotherapyNRNRLUX-Lung 711Schuler M. Tan E.H. O’Byrne K. et al.First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.J Cancer Res Clin Oncol. 2019; 145: 1569-1579Crossref PubMed Scopus (26) Google ScholarAfatinib12.70.760 (0.550–1.060)10.90.710 (0.470–1.060)Gefitinib11.010.8FLAURA12Soria J.C. Ohe Y. Vansteenkiste J. et al.Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer.N Engl J Med. 2018; 378: 113-125Crossref PubMed Scopus (2332) Google Scholar,13Planchard D. Boyer M.J. Lee J.S. et al.Postprogression outcomes for osimertinib versus standard-of-care EGFR-TKI in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer.Clin Cancer Res. 2019; 25: 2058-2063Crossref PubMed Scopus (39) Google ScholarOsimertinib21.40.430 (0.320–0.560)14.40.510 (0.360–0.710)Gefitinib or erlotinib11.09.5FLAURA China14Cheng Y. He Y. Li W. et al.Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study.Target Oncol. 2021; 16: 165-176Crossref PubMed Scopus (22) Google ScholarOsimertinibNR0.410 (0.220–0.770)NR0.690 (0.390–1.210)GefitinibNRNRJO2556717Seto T. Kato T. Nishio M. et al.Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.Lancet Oncol. 2014; 15: 1236-1244Abstract Full Text Full Text PDF PubMed Scopus (581) Google Scholar,18Yamamoto N. Seto T. Nishio M. et al.Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: survival follow-up results of the randomized JO25567 study.Lung Cancer. 2021; 151: 20-24Abstract Full Text Full Text PDF PubMed Scopus (22) Google ScholarErlotinib + bevacizumab18.00.410 (0.240–0.720)13.90.670 (0.380–1.180)Erlotinib10.37.1NEJ02619Saito H. Fukuhara T. Furuya N. et al.Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.Lancet Oncol. 2019; 20: 625-635Abstract Full Text Full Text PDF PubMed Scopus (308) Google Scholar,20Maemondo M. Fukuhara T. Saito H. et al.NEJ026: final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.J Clin Oncol. 2020; 38 (9506–9506)Google ScholarErlotinib + bevacizumab17.40.570 (0.330–0.970)16.60.690 (0.410–1.160)Erlotinib13.712.4ARTEMIS22Zhou Q. Wu Y.L. Cheng Y.C. et al.CTONG 1509: phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC.Ann Oncol. 2019; 30: v603Abstract Full Text PDF Google ScholarErlotinib + bevacizumab17.90.620 (0.410–0.920)19.50.510 (0.330–0.790)Erlotinib12.57.9RELAY23Nakagawa K. Garon E.B. Seto T. et al.Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol. 2019; 20: 1655-1669Abstract Full Text Full Text PDF PubMed Scopus (258) Google ScholarErlotinib + ramucirumab19.60.650 (0.470–0.900)19.40.620 (0.440–0.870)Erlotinib12.511.2ACTIVE21Zhao H. Yao W. Min X. et al.Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC: the phase III ACTIVE study (CTONG1706).J Thorac Oncol. 2021; 16: 1533-1546Abstract Full Text Full Text PDF PubMed Scopus (21) Google ScholarGefitinib + apatinib15.60.670 (0.450–0.990)12.00.720 (0.480–1.090)Gefitinib13.711.2CI, confidence interval; HR, hazard ratio; NR, not reported; PFS, progression-free survival. Open table in a new tab Table 2OS of Patients With NSCLC Harboring EGFR Exon 19 Deletion and 21L858R MutationTrialsTreatmentExon 19 DeletionExon 21 L858R MutationOS (mo)HR (95% CI)OS (mo)HR (95% CI)EURTAC2Rosell R. Carcereny E. Gervais R. et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.Lancet Oncol. 2012; 13: 239-246Abstract Full Text Full Text PDF PubMed Scopus (4284) Google ScholarErlotinib30.4NR17.7NRChemotherapy18.917.5ENSURE3Wu Y.L. Zhou C. Liam C.K. et al.First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.Ann Oncol. 2015; 26: 1883-1889Abstract Full Text Full Text PDF PubMed Scopus (515) Google ScholarErlotinib24.00.79 (0.480–1.300)27.21.050 (0.600–1.840)Chemotherapy26.725.3OPTIMAL4Zhou C. Wu Y.L. Chen G. et al.Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).Ann Oncol. 2015; 26: 1877-1883Abstract Full Text Full Text PDF PubMed Scopus (337) Google ScholarErlotinib27.01.52 (0.910–2.520)21.50.920 (0.550–1.540)Chemotherapy31.518.3WJTOG34055Mitsudomi T. Morita S. Yatabe Y. et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.Lancet Oncol. 2010; 11: 121-128Abstract Full Text Full Text PDF PubMed Scopus (3474) Google ScholarGefitinib31.8NR34.8NRChemotherapy41.635.3CONVINCE6Shi Y.K. Wang L. Han B.H. et al.First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study.Ann Oncol. 2017; 28: 2443-2450Abstract Full Text Full Text PDF PubMed Scopus (171) Google ScholarIcotinib32.30.83 (0.550–1.270)29.11.140 (0.740–1.760)Chemotherapy38.826.7ARCHER 1009 and A74710287Ramalingam S.S. O’Byrne K. Boyer M. et al.Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.Ann Oncol. 2016; 27: 1363Abstract Full Text Full Text PDF PubMed Scopus (1) Google ScholarDacomitinib26.60.72 (0.356–1.412)26.90.690 (0.276–1.717)Erlotinib24.219.8ARCHER 10508Wu Y.L. Cheng Y. Zhou X. et al.Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.Lancet Oncol. 2017; 18: 1454-1466Abstract Full Text Full Text PDF PubMed Scopus (634) Google Scholar,9Mok T.S. Cheng Y. Zhou X. et al.Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations.Drugs. 2021; 81: 257-266Crossref PubMed Scopus (21) Google ScholarDacomitinib34.10.88 (0.613–1.262)32.50.710 (0.478–1.045)GefitinibNR23.2LUX-Lung 310Yang J.C. Wu Y.L. Schuler M. et al.Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.Lancet Oncol. 2015; 16: 141-151Abstract Full Text Full Text PDF PubMed Scopus (1157) Google ScholarAfatinib33.30.54 (0.360–0.790)27.61.300 (0.800–2.110)Chemotherapy21.140.3LUX-Lung 610Yang J.C. Wu Y.L. Schuler M. et al.Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.Lancet Oncol. 2015; 16: 141-151Abstract Full Text Full Text PDF PubMed Scopus (1157) Google ScholarAfatinib31.40.64 (0.440–0.940)19.61.220 (0.810–1.830)Chemotherapy18.424.3LUX-Lung 711Schuler M. Tan E.H. O’Byrne K. et al.First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.J Cancer Res Clin Oncol. 2019; 145: 1569-1579Crossref PubMed Scopus (26) Google ScholarAfatinib30.70.83 (0.580–1.170)25.00.910 (0.620–1.360)Gefitinib26.421.2FLAURA12Soria J.C. Ohe Y. Vansteenkiste J. et al.Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer.N Engl J Med. 2018; 378: 113-125Crossref PubMed Scopus (2332) Google Scholar,13Planchard D. Boyer M.J. Lee J.S. et al.Postprogression outcomes for osimertinib versus standard-of-care EGFR-TKI in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer.Clin Cancer Res. 2019; 25: 2058-2063Crossref PubMed Scopus (39) Google ScholarOsimertinibNR0.679 (0.509–0.904)NR0.996 (0.708–1.404)Gefitinib or erlotinibNRNRFLAURA China14Cheng Y. He Y. Li W. et al.Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study.Target Oncol. 2021; 16: 165-176Crossref PubMed Scopus (22) Google ScholarOsimertinibNR0.610 (0.320–1.180)NR1.020 (0.590–1.780)GefitinibNRNRJO2556717Seto T. Kato T. Nishio M. et al.Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.Lancet Oncol. 2014; 15: 1236-1244Abstract Full Text Full Text PDF PubMed Scopus (581) Google Scholar,18Yamamoto N. Seto T. Nishio M. et al.Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: survival follow-up results of the randomized JO25567 study.Lung Cancer. 2021; 151: 20-24Abstract Full Text Full Text PDF PubMed Scopus (22) Google ScholarErlotinib + bevacizumab53.20.790 (0.440–1.440)43.60.830 (0.460–1.490)Erlotinib50.342.1NEJ02619Saito H. Fukuhara T. Furuya N. et al.Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.Lancet Oncol. 2019; 20: 625-635Abstract Full Text Full Text PDF PubMed Scopus (308) Google Scholar,20Maemondo M. Fukuhara T. Saito H. et al.NEJ026: final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.J Clin Oncol. 2020; 38 (9506–9506)Google ScholarErlotinib + bevacizumab41.91.340 (0.760–2.370)50.70.790 (0.460–1.360)ErlotinibNR38.2ARTEMIS22Zhou Q. Wu Y.L. Cheng Y.C. et al.CTONG 1509: phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC.Ann Oncol. 2019; 30: v603Abstract Full Text PDF Google ScholarErlotinib + bevacizumabNRNRNRNRErlotinibNRNRRELAY23Nakagawa K. Garon E.B. Seto T. et al.Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol. 2019; 20: 1655-1669Abstract Full Text Full Text PDF PubMed Scopus (258) Google ScholarErlotinib + ramucirumabNRNRNRNRErlotinibNRNRACTIVE21Zhao H. Yao W. Min X. et al.Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC: the phase III ACTIVE study (CTONG1706).J Thorac Oncol. 2021; 16: 1533-1546Abstract Full Text Full Text PDF PubMed Scopus (21) Google ScholarGefitinib + apatinibNRNRNRNRGefitinibNRNRCI, confidence interval; HR, hazard ratio; NR, not reported; OS, overall survival. Open table in a new tab CI, confidence interval; HR, hazard ratio; NR, not reported; PFS, progression-free survival. CI, confidence interval; HR, hazard ratio; NR, not reported; OS, overall survival. Thus, our team speculates that EGFR ex19del and ex21L858R cannot be taken as an independent predictor of efficacy and prognosis. Probably, other than EGFR ex19del and ex21L858R, there exist deeper mechanisms and reasons that affect the efficacy of EGFR TKIs and the prognosis of EGFR-mutant NSCLC. The possible reason is that most of the above-mentioned first-line monotherapy or combination therapy randomized controlled trials used first-generation sequencing. So, only EGFR mutations are detected whereas concomitant mutation information is missing, causing the roles of EGFR ex19del and ex21L858R could be magnified. The status of concomitant mutation in EGFR-mutant NSCLC seemed not been well emphasized and valued even in the era of next-generation sequencing (NGS). Recently, growing evidence suggested that the concomitant mutation was associated with the reduced efficacy of EGFR TKIs and worsens survival benefit in EGFR-mutant NSCLC.24Hong S. Gao F. Fu S. et al.Concomitant genetic alterations with response to treatment and epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR-mutant advanced non-small cell lung cancer.JAMA Oncol. 2018; 4: 739-742Crossref PubMed Scopus (90) Google Scholar,25Kim Y. Lee B. Shim J.H. et al.Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced NSCLC.J Thorac Oncol. 2019; 14: 193-202Abstract Full Text Full Text PDF PubMed Scopus (62) Google Scholar Moreover, study from our team has formerly revealed that the concomitant mutation profile between EGFR ex19del and ex21L858R was different. It was reported that the incidence of concomitant mutation was higher in patients with EGFR ex21L858R mutation compared with those with EGFR ex19del,24Hong S. Gao F. Fu S. et al.Concomitant genetic alterations with response to treatment and epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR-mutant advanced non-small cell lung cancer.JAMA Oncol. 2018; 4: 739-742Crossref PubMed Scopus (90) Google Scholar whereas another study revealed that concomitant mutation was slightly higher with EGFR ex19del.26Blakely C.M. Watkins T.B.K. Wu W. et al.Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.Nat Genet. 2017; 49: 1693-1704Crossref PubMed Scopus (297) Google Scholar With the extensive advances in genome sequencing technology, we are deemed to find that there are more complex genetic factors beneath the simple classification of EGFR ex19del and ex21L858R, which will determine the efficacy of EGFR TKIs and prognosis of EGFR-mutant NSCLC. We believe that in the era of NGS, first-line treatment decisions for patients with EGFR-mutant NSCLC should be made on the basis of the comprehensive information from NGS and the status of coexisting mutations other than EGFR ex19del and ex21L858R mutations. For patients with NSCLC with activating EGFR mutations, there will be numerous detected concomitant mutations if whole-genome sequencing method was performed, but, honestly, not every concomitant mutation can be used to predict the efficacy of EGFR TKIs. Therefore, how to precisely define or conclude the meaningful concomitant mutations is a next-step problem that needs further investigation. TP53 is an important tumor suppressor gene,27Kastenhuber E.R. Lowe S.W. Putting p53 in context.Cell. 2017; 170: 1062-1078Abstract Full Text Full Text PDF PubMed Scopus (816) Google Scholar and accumulating evidence is suggesting patients with EGFR-mutant NSCLC concomitant with TP53 mutation have a worse response to EGFR TKIs and survival outcome tendency.28Jiao X.D. Qin B.D. You P. Cai J. Zang Y.S. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.Lung Cancer. 2018; 123: 70-75Abstract Full Text Full Text PDF PubMed Scopus (55) Google Scholar,29Molina-Vila M.A. Bertran-Alamillo J. Gascó A. et al.Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer.Clin Cancer Res. 2014; 20: 4647-4659Crossref PubMed Scopus (97) Google Scholar Notably, concomitant TP53 exon 8 mutation was associated with a distinctly shorter PFS and overall survival in patients with EGFR-mutant NSCLC when compared with other exon subsets,30Canale M. Petracci E. Delmonte A. et al.Impact of mutations on outcome in -mutated patients treated with first-line tyrosine kinase inhibitors.Clin Cancer Res. 2017; 23: 2195-2202Crossref PubMed Scopus (147) Google Scholar which is consistent with subgroup results of the ACTIVE study. Furthermore, not only TP53 mutation but also other meaningful disease-associated gene mutations captured by the advancing sequencing technology were worthy of further investigation in the setting of EGFR-mutant NSCLC. Hongyun Zhao: Conceptualization, Writing—original draft, Writing—review and editing. Zhonghan Zhang: Writing—original draft. Li Zhang: Conceptualization, Writing—review and editing. The Role of Dual Inhibition of EGFR and Vascular Endothelial Growth Factor (Receptor) in the Treatment of NSCLC With EGFR MutationJournal of Thoracic OncologyVol. 16Issue 9PreviewIn the phase 3 ACTIVE study (CTONG1706), apatinib plus gefitinib has been found to have a significant improvement in the primary end point of the study, progression-free survival, compared with placebo plus gefitinib in patients with advanced NSCLC and EGFR mutation in the first-line setting.1 This result is in line with preceding clinical studies investigating the efficacy of combination therapies with an EGFR-tyrosine kinase inhibitor (TKI) and vascular endothelial growth factor (VEGF) or VEGF-receptor (VEGFR) inhibitor. Full-Text PDF